Effects of rosiglitazone on the growth and lymphangiogenesis of human gastric cancer transplanted in nude mice

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 2705-2712

  Chen, Fang Zhi ^a,b   Mo, Xi Ming ^c   Wang, Qing Ping ^b   Li, Jun ^a   Zhang, Li ^a  

^a UNIVERSITY OF SOUTH CHINA   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Gastric cancer; Lymphangiogenesis; Peroxisome proliferator activated receptor ; Rosiglitazone

Indexed keywords

MESSENGER RNA; ROSIGLITAZONE; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CAPILLARY DENSITY; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPHANGIOGENESIS; LYMPHATIC VESSEL DENSITY; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MICE; MICE, NUDE; RNA, MESSENGER; STOMACH NEOPLASMS; THIAZOLIDINEDIONES; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84892396110     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2704     Document Type: Article

References (46)

1. Brenner H, Rothenbacher D and Arndt V: Epidemiology of stomach cancer. Methods Mol Biol 472: 467-477, 2009.
2. Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907, 2010.
3. Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725-730, 2001.
4. Achen MG and Stacker SA: Molecular control of lymphatic metastasis. Ann NY Acad Sci 1131: 225-234, 2008.
5. Alitalo K, Tammela T and Petrova TV: Lymphangiogenesis in development and human disease. Nature 438: 946-953, 2005.
6. Mumprecht V and Detmar M: Lymphangiogenesis and cancer metastasis. J Cell Mol Med 13: 1405-1416, 2009.
7. McCarter MD, Clarke JH and Harken AH: Lymphangiogenesis is pivotal to the trials of a successful cancer metastasis. Surgery 135: 121-124, 2004.
8. Matsumoto M, Roufail S, Inder R, et al: Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis. Clin Exp Metastasis: Apr 17, 2013 (Epub ahead of print).
9. Saltiel AR and Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45: 1661-1669, 1996.
10. He Q, Pang R, Song X, et al: Rosiglitazone suppresses the growth and invasiveness of SGC-7901 gastric cancer cells and angiogenesis in vitro via PPARγ dependent and independent mechanisms. PPAR Res 2008: 649808, 2008.
11. Zhang L, Hu JF, Li GQ, Xiao X and Su Q: Rosiglitazone reverses mitomycin C resistance in human gastric cancer cells. Am J Med Sci 343: 382-387, 2012.
12. Talbert DR, Allred CD, Zaytseva YY and Kilgore MW: Transactivation of ERα by Rosiglitazone induces proliferation in breast cancer cells. Breast Cancer Res Treat 108: 23-33, 2008.
13. Miao R, Xu T, Liu L, et al: Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell line. Exp Ther Med 2: 413-417, 2011.
14. Cerquetti L, Sampaoli C, Amendola D, et al: Rosiglitazone induces autophagy in H295R and cell cycle deregulation in SW13 adrenocortical cancer cells. Exp Cell Res 317: 1397-1410, 2011.
15. Chiu SJ, Hsaio CH, Tseng HH, et al: Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells. Biochem Biophys Res Commun 394: 774-779, 2010.
16. Lyon CM, Klinge DM, Do KC, et al: Rosiglitazone prevents the progression of preinvasive lung cancer in a murine model. Carcinogenesis 30: 2095-2099, 2009.
17. Yee LD, Williams N, Wen P, et al: Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res 13: 246-252, 2007.
18. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, et al: Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol 71: 63-72, 2013.
19. Luconi M, Mangoni M, Gelmini S, et al: Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. Endocr Relat Cancer 17: 169-177, 2010.
20. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA and Hamilton SM: Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 241: 27-39, 2005.
21. Ohno M, Nakamura T, Kunimoto Y, Nishimura K, Chung-Kang C and Kuroda Y: Lymphagenesis correlates with expression of vascular endothelial growth factor-C in colorectal cancer. Oncol Rep 10: 939-943, 2003.
22. Mangelsdorf DJ, Thummel C, Beato M, et al: The nuclear receptor superfamily: the second decade. Cell 83: 835-839, 1995.
23. Siersbaek R, Nielsen R and Mandrup S: PPARγ in adipocyte differentiation and metabolism - novel insights from genome-wide studies. FEBS Lett 584: 3242-3249, 2010.
24. Nedergaard J, Petrovic N, Lindgren EM, Jacobsson A and Cannon B: PPARγ in the control of brown adipocyte differentiation. Biochim Biophys Acta 1740: 293-304, 2005.
25. Fernyhough ME, Okine E, Hausman G, Vierck JL and Dodson MV: PPARγ and GLUT-4 expression as developmental regulators/markers for preadipocyte differentiation into an adipocyte. Domest Anim Endocrinol 33: 367-378, 2007.
26. Elrod HA and Sun SY: PPARγ and apoptosis in cancer. PPAR Res 2008: 704165, 2008.
27. Kim S, Lee JJ and Heo DS: PPARã ligands induce growth inhibition and apoptosis through p63 and p73 in human ovarian cancer cells. Biochem Biophys Res Commun 406: 389-395, 2011.
28. Zhou J, Zhang W, Liang B, et al: PPARγ activation induces autophagy in breast cancer cells. Int J Biochem Cell Biol 41: 2334-2342, 2009.
29. Zaytseva YY, Wallis NK, Southard RC and Kilgore MW: The PPARγ antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARγ-dependent and -independent mechanisms. Anticancer Res 31: 813-823, 2011.
30. Kitamura S, Miyazaki Y, Hiraoka S, et al: PPARγ inhibits the expression of c-MET in human gastric cancer cells through the suppression of Ets. Biochem Biophys Res Commun 265: 453-456, 1999.
31. Takahashi H, Hosono K, Uchiyama T, et al: PPARγ ligand as a promising candidate for colorectal cancer chemoprevention: a pilot study. PPAR Res 2010: 257835, 2010. doi: 10.1155/2010/257835.
32. Wood WM, Sharma V, Bauerle KT, et al: PPARγ promotes growth and invasion of thyroid cancer cells. PPAR Res 2011: 171765, 2011. doi: 10.1155/2011/171765.
33. Sato H, Ishihara S, Kawashima K, et al: Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists. Br J Cancer 83: 1394-1400, 2000.
34. Lu J, Imamura K, Nomura S, et al: Chemopreventive effect of peroxisome proliferator-activated receptor γ on gastric carcinogenesis in mice. Cancer Res 65: 4769-4774, 2005.
35. Chen J, Zhi Y, Chang X, Zhang S and Dai D: Expression of ADAMTS1 and its correlation with angiogenesis in primary gastric cancer and lymph node metastasis. Dig Dis Sci 58: 405-413, 2013.
36. Wu H, Xin Y, Xu C and Xiao Y: Capecitabine combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts. Exp Ther Med 3: 650-654, 2012.
37. Fidler IJ: The biology of cancer metastasis. Semin Cancer Biol 21: 71, 2011.
38. Al-Rawi MA and Jiang WG: Lymphangiogenesis and cancer metastasis. Front Biosci 16: 723-739, 2011.
39. Raica M, Cimpean AM and Ribatti D: The role of podoplanin in tumor progression and metastasis. Anticancer Res 28: 2997-3006, 2008.
40. Yu JW, Wu JG, Tajima Y, et al: Study on lymph node metastasis correlated to lymphangiogenesis, lymphatic vessel invasion, and lymph node micrometastasis in gastric cancer. J Surg Res 168: 188-196, 2011.
41. Makinen T, Veikkola T, Mustjoki S, et al: Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 20: 4762-4773, 2001.
42. Van Trappen PO, Steele D, Lowe DG, et al: Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J Pathol 201: 544-554, 2003.
43. Su JL, Chen PS, Chien MH, et al: Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells. Cancer Cell 13: 557-560, 2008.
44. Takizawa H, Kondo K, Fujino H, et al: The balance of VEGF-C and VEGFR-3 mRNA is a predictor of lymph node metastasis in non-small cell lung cancer. Br J Cancer 95: 75-79, 2006.
45. Arigami T, Natsugoe S, Uenosono Y, et al: Vascular endothelial growth factor-C and -D expression correlates with lymph node micrometastasis in pN0 early gastric cancer. J Surg Oncol 99: 148-153, 2009.
46. Liu ZY, Qiu HO, Yuan XJ, et al: Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin. Int J Oncol 41: 1762-1772, 2012.